Medications for ADHD
What stimulants and non-stimulants are used for ADHD, when to pick which, and what the cardiac and growth monitoring picture looks like.
First-line options
Stimulants
Two chemical families, both first-line. Neither is clearly better in trials, and many patients respond to one and not the other, so if the first family fails, the second is worth trying.
Amphetamines
Amphetamine mixed salts (Adderall, Mydayis, Adderall XR) covers 4 to 12 hours depending on formulation. IR is 4 to 6 hours, XR is 10 to 12. Adderall XR uses a bimodal bead system. Mydayis extends to about 16 hours.
Lisdexamfetamine (Vyvanse) is a prodrug that gets cleaved by red blood cells into dextroamphetamine. Onset is more gradual, effect lasts 12 to 14 hours, and the abuse potential is lower than IR amphetamines because it can't be snorted or injected effectively. Approved for ADHD and binge eating disorder.
Dextroamphetamine (Dexedrine, Zenzedi, ProCentra liquid) is the d-isomer alone. Similar in profile to mixed amphetamine salts with slightly different subjective feel.
Methamphetamine (Desoxyn) is on the shelf for ADHD but rarely used because of the reputation and abuse potential.
Methylphenidate
Methylphenidate (Ritalin, Concerta, Focalin, Metadate, Daytrana, Ritalin LA, Cotempla) is available in dozens of formulations. IR is 3 to 4 hours. Concerta (OROS) is 10 to 12 hours with a gradually rising delivery. Daytrana is a transdermal patch (9 to 12 hours after peel-off). Cotempla is an orally disintegrating tablet.
Dexmethylphenidate (Focalin, Focalin XR) is the d-isomer of methylphenidate. Roughly twice as potent per milligram as racemic methylphenidate.
Serdexmethylphenidate-dexmethylphenidate (Azstarys) is a combination of a prodrug and immediate-release dexmethylphenidate. Rapid onset with a long tail.
For a fuller comparison, see the ADHD medications class page.
Non-stimulants
Non-stimulants work more slowly (weeks to full effect) and generally produce a smaller effect size than stimulants. They're first-line when stimulants aren't the right fit, and they're reasonable augments to stimulants.
Atomoxetine (Strattera) is a norepinephrine reuptake inhibitor. FDA-approved for children and adults. Onset is 2 to 4 weeks for behavioral effects, up to 8 weeks for full effect. Common side effects include GI upset, decreased appetite, fatigue, and (rarely) suicidal ideation in children and adolescents. Dosing is typically 40 to 100 mg once daily in adults, weight-based in children.
Viloxazine (Qelbree) is another norepinephrine reuptake inhibitor, approved 2021. Faster onset than atomoxetine, similar profile. Interacts with CYP1A2 substrates.
Guanfacine (Intuniv extended-release) is an alpha-2A agonist. FDA-approved for ADHD in children and adolescents (6 to 17), and used off-label in adults. Sedation and hypotension are the main side effects. Useful in ADHD with prominent hyperactivity, tics, or emotional dysregulation. Can be used as monotherapy or added to a stimulant.
Clonidine (Kapvay extended-release) is another alpha-2 agonist. Similar to guanfacine but more sedating. Often dosed at bedtime, sometimes helpful for sleep problems in ADHD.
Second-line and augmentation
Adding a non-stimulant to a stimulant
A common pattern: a stimulant covers the school or work day but wears off in the late afternoon, or the stimulant helps focus but doesn't help with emotional regulation. Adding guanfacine ER (or clonidine ER) is a well-supported combination in that scenario. Both can be added to any stimulant. See the ADHD medications class page.
Combining atomoxetine or viloxazine with a stimulant is done, though the evidence base is thinner.
Bupropion
Bupropion has reasonable off-label evidence for ADHD, particularly in adults. It's the pick when ADHD is comorbid with depression, when stimulants aren't tolerated, or when a stimulant isn't clinically appropriate (substance use history in particular).
Wake-promoting agents (off-label)
Modafinil and armodafinil have some off-label use in adult ADHD, particularly for the fatigue and low-arousal aspects. Not FDA-approved for ADHD. Solriamfetol has similar off-label uses.
TCAs
Older options like desipramine and nortriptyline have some evidence in ADHD, mostly for children who couldn't take stimulants. Rarely used now, mainly because of cardiac and overdose concerns.
When to consider a different approach
Stimulants aren't the right fit
Several scenarios shift the algorithm away from stimulants as first line:
- Active substance use disorder, especially stimulant use disorder. Lisdexamfetamine has a lower abuse potential than IR options and is sometimes tried, but non-stimulants are usually favored.
- Significant cardiac disease, uncontrolled hypertension, or family history of sudden cardiac death.
- Untreated glaucoma.
- Concurrent MAOI use (contraindicated).
- Severe anxiety that hasn't been addressed yet. Stimulants can worsen anxiety.
- Bipolar disorder without a mood stabilizer on board. Stimulants can precipitate mania.
- Tics or Tourette's. Stimulants can worsen tics in some patients (though the effect is smaller than historical concern suggested). Guanfacine or atomoxetine tend to be favored.
In those cases, atomoxetine, viloxazine, guanfacine, or clonidine become first-line options.
Partial response
If a stimulant is helping some but not enough, options include increasing the dose (within FDA and clinical limits), switching to the other stimulant family (amphetamine to methylphenidate or vice versa), lengthening duration (adding an afternoon short-acting on top of a morning long-acting), or adding a non-stimulant.
Refractory ADHD
If two stimulant trials (one from each family) and a non-stimulant trial haven't worked, the diagnosis should be revisited. Untreated sleep disorder, depression, anxiety, substance use, and thyroid disease all mimic ADHD. So does chronic sleep deprivation from an unrelated cause. Comorbidities that need their own treatment often explain why the ADHD medication isn't landing.
Special considerations
Baseline cardiac assessment
Stimulants raise heart rate and blood pressure, usually modestly. Before starting a stimulant, the standard workup includes:
- History focused on cardiac symptoms (syncope, exertional chest pain, palpitations).
- Family history focused on sudden cardiac death, particularly under age 40.
- Physical exam.
- Baseline blood pressure and heart rate.
Routine ECG is not required for otherwise healthy patients with a negative history and exam. ECG is warranted with a positive history or family history, or with prior cardiac disease. AAP and AHA guidance align on this.
Growth monitoring in children
Stimulants can slow growth velocity in children. The effect on final adult height is small (roughly 1 to 3 cm on average), but growth (height and weight) should be tracked. Structured drug holidays (weekends, summers) are sometimes used, though the evidence for their utility on final height is limited. Nutritional counseling and evening protein snacks help with appetite suppression.
Sleep
Stimulants can worsen sleep. Later dosing, higher doses, or short-acting formulations in the afternoon are the usual culprits. Adjusting the timing of the last dose is the first move. Guanfacine or clonidine at bedtime can help both ADHD and sleep. Trazodone, melatonin, or CBT-I are reasonable additions.
Cardiovascular disease in adults
For adults with hypertension or ischemic heart disease, non-stimulants are often favored. If a stimulant is used, blood pressure and heart rate need monitoring. Guanfacine and clonidine (both antihypertensive in origin) can be useful in ADHD with mild hypertension. See the Beers Criteria reference for the older adult picture.
Pregnancy
Stimulant use in pregnancy is a nuanced decision. Data are mixed on teratogenicity, and untreated ADHD carries its own risks (impulsivity, accidents, poor prenatal care). Bupropion is often the non-stimulant of choice in pregnancy. Atomoxetine data are limited. Individual risk-benefit conversations are the norm. See the pregnancy safety reference.
Substance use disorder
ADHD is common in patients with substance use disorders, and treating ADHD may reduce substance use. Lisdexamfetamine is often the first stimulant tried in this population because of lower abuse liability. Atomoxetine, viloxazine, guanfacine, and bupropion are non-stimulant options. Coordinated care with the treating clinician for the substance use disorder matters.
Comorbid anxiety
Stimulants can worsen anxiety, particularly at initial doses. Options include starting low and titrating slowly, treating the anxiety first with an SSRI, or using a non-stimulant. Guanfacine sometimes helps with both.
Comorbid depression
If ADHD and depression coexist, treating both is standard. Bupropion covers both to some extent. An SSRI plus a stimulant is a compatible combination. See comorbidity medication selection.
What tips the choice
- No strong contraindications, wants next-day effect: a stimulant. Amphetamine or methylphenidate; either is reasonable to start.
- Long day (school plus after-school activities): lisdexamfetamine or Concerta or Adderall XR. Extended-release with 10 to 14 hours of coverage.
- Late-afternoon rebound: add a short-acting IR stimulant, or switch to a longer formulation, or add guanfacine ER.
- Substance use history: lisdexamfetamine (lower abuse potential) or a non-stimulant.
- Cardiac risk: non-stimulant first. Guanfacine or clonidine, or atomoxetine, or viloxazine.
- Tics: guanfacine or atomoxetine.
- Anxiety comorbid: treat anxiety first, or use atomoxetine or viloxazine, or add guanfacine.
- Sleep problems: earlier last stimulant dose, or add clonidine at bedtime, or guanfacine.
- Adult with depression comorbid: bupropion covers both partially, or SSRI plus stimulant.
- Insurance won't cover a stimulant right away: IR methylphenidate or IR mixed amphetamine salts are cheap and generic.
- Prior good response in a family member: worth leaning toward that molecule. Stimulant response has some familial pattern.
Common questions
Are stimulants addictive? They have abuse potential, and they're Schedule II controlled substances. For patients with ADHD who take them as prescribed, addiction is uncommon, and treatment often reduces rather than increases substance use overall. The higher-risk situations are IR formulations at higher doses, in patients with prior substance use histories, in adolescents and young adults. Lisdexamfetamine has a lower abuse potential than other stimulants because of how it's activated in the body.
How do I know if the medication is working? The signs are usually clear within a few days for stimulants: better focus, less impulsivity, longer attention span for tasks. Rating scales (Vanderbilt, ASRS, Conners) can quantify the change. If nothing has shifted at an adequate dose after 1 to 2 weeks, the medication probably isn't the right one for this patient, and switching (either dose, formulation, or family) is the next move.
Do I have to take it every day? For many patients, especially adults, yes. ADHD is a chronic condition, and the medication works while it's in the system. Some children take drug holidays on weekends or during summers to reduce cumulative side effects (appetite, growth), but that's a discussion with the prescriber. For adults, most benefit comes from consistent daily use.
What if I feel like a zombie or lose my personality? That's not the goal, and it's a sign the dose is too high or the medication isn't right. A well-titrated stimulant should feel like better focus without feeling flat, tense, or numb. Talk to the prescriber. Lowering the dose or switching molecules usually fixes it.
Can adults be diagnosed with ADHD? Yes. Adult ADHD is common (roughly 4% prevalence), often missed in childhood, and often presents with less overt hyperactivity than in children. Diagnosis requires symptoms present before age 12 and current functional impairment. Treatment for adults is the same algorithm as for children, with stimulants first-line and non-stimulants in second line. Response rates are similar.
Sources
This guide draws on current prescribing information, treatment guidelines, and public health references. It is reviewed for clinical accuracy and updated as guidance changes.
- American Academy of Pediatrics. Clinical practice guideline for the diagnosis, evaluation, and treatment of ADHD.
- American Academy of Child and Adolescent Psychiatry. Practice parameters for ADHD.
- National Institute of Mental Health. Attention-deficit/hyperactivity disorder.
- MedlinePlus, U.S. National Library of Medicine.
THE KNOWLEDGE PATH
Walk this topic outward.
- GUIDE Medications for ADHD (current)
- CLASS SSRIs
- MEDICATION Sertraline (Zoloft)
- CONDITION Major Depressive Disorder (on Shrinkopedia)
- CARE Consider depression evaluation at shrinkMD
The Knowledge Path is a curated walk. Every step is one decision away from the next.
Managing a medication needs a prescriber
Any psychiatric medication has to be started and adjusted by a clinician who can follow you over time. If you don't have a prescriber, our guides section explains the options, including in-person care and telepsychiatry, and how to choose between them.